New prostate cancer test improves risk assessment

May 8, 2013, University of California, San Francisco

(Medical Xpress)—A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study. The test, which improves risk assessment when patients are first diagnosed, can also aid in determining which men are suitable for active surveillance – a way of managing the disease without direct treatment.

Prostate cancer often grows slowly, and many of the quarter-million patients diagnosed annually in the United States never need treatment, which typically involves surgery, radiation or both. Still, most patients with low-risk prostate cancer in this country immediately undergo treatment.

The researchers found the new test provides "statistically significant and clinically meaningful" prognostic information, and can help identify many more low-risk who could safely choose surveillance, sparing them from unnecessary treatment and avoidable . At the same time, the test can pinpoint men at apparent low-risk who in fact may have potentially , the authors said.

The independent UCSF clinical study of 395 men validated the Oncotype DX Genomic Prostate Score (GPS), a biopsy-based pretreatment tool of Genomic Health, Inc. as a predictor of high grade or extracapsular prostate cancer.

Results will be presented on May 8, 2013, during the American Urological Association's annual meeting in San Diego.

"With the , we can more confidently recommend when it is appropriate,'' said the study's lead author Matthew R. Cooperberg, MD, MPH, a UCSF assistant professor of urology and & biostatistics. "And patients through active surveillance can avoid or delay surgery or radiation for their condition.

"Active surveillance is increasingly acknowledged as a preferred strategy for most men with low-risk disease, but in practice it is used relatively infrequently," he noted. "There are many reasons why – financial, legal and cultural among others. Many men don't want to live with anxiety over the chances of their disease progressing. So we need to predict with better accuracy which tumors harbor metastatic potential. If we are able to risk-stratify men more consistently and identify a greater proportion for active surveillance, we should be able to ameliorate overtreatment rates, and by extension help resolve the ongoing debate about PSA screening."

The second most common cancer in men, prostate cancer affects about one man in six, according to the American Cancer Society. Typically the disease occurs in older men – the average age at diagnosis is about 67 – and an aggressive form kills as many as 30,000 men annually in the U.S. Most men, however, do not die from the disease because they have relatively indolent, low-risk tumors that do not progress even without treatment.

Active surveillance involves closely monitoring a patient's condition through serial PSA screening and prostate biopsies, but otherwise the disease is not treated unless tests show the condition is getting worse. Active surveillance is not entirely benign – biopsies are uncomfortable and carry a risk of bleeding and infection. Moreover, some patients experience a higher level of anxiety over the potential of their cancers to advance.

While active surveillance can help patients avoid or delay surgery or , scientists have faced a major challenge: how to identify – consistently and reliably – which patients can safely embark on it and which patients face clinically meaningful risk of disease progression.

In the new UCSF study, investigators evaluated the ability of the 17-gene assay through prostate needle biopsy specimens to predict pathologic stage and grade at prostatectomy. The researchers focused on whether the test's biomarkers added independent predictive information beyond what could already be determined about a patient through standard PSA, Gleason grade and detail variables.

The men in the study, identified from the UCSF Helen Diller Family Comprehensive Cancer Center Urologic Oncology Database, ranged from 38 to 77 years old at the time they were diagnosed – the median age was 58. The patients represented a range of low and intermediate risk tumors in terms of clinical risk characteristics.

The researchers found that the test "contributed statistically significant, and clinically meaningful, additional prognostic information above and beyond existing, previously well-validated clinical risk stratification instruments."

The authors noted a number of study limitations including an explicit intention to include men whose tumors were expected to show a wider range of risk. Further, they said with additional study, the test might be used to identify men with particularly low risk tumors who might be candidates for less-intense surveillance requiring – for example – fewer biopsies.

The test will be available to physicians and patients following the presentation of data on May 8.

" is under great scrutiny by many – patients, providers and others in the health care industry," said senior author Peter R. Carroll, MD, MPH, professor and chair of the UCSF Department of . "Although mortality rates have declined 40 percent since the advent of PSA testing, it has come at the expense of identifying many men with very low grade, slow growing cancers that would not have required treatment if their cancers were left undetected. Over-detection is compounded by over-treatment, the treatment of such slow growing cancers. Because of this, many have argued that we stop using serum PSA, but this would reverse the gains in survival witnessed over the last two decades.

"The way forward is to promote more personalized decision-making, information not currently available and unique to an individual's cancer. Such information will allow both and providers to better balance the risks and benefits of either treatment or careful in lieu of immediate treatment."

Explore further: Active surveillance can reduce suffering among men with prostate cancer

Related Stories

Active surveillance can reduce suffering among men with prostate cancer

November 2, 2012
With active surveillance many men with prostate cancer could dispense with radiation treatment and surgery, and thus avoid adverse effects such as incontinence and impotence. This is the outcome of a study of almost 1,000 ...

Recommendation against PSA test too drastic: WU expert

May 22, 2012
(Medical Xpress) -- A new recommendation issued today by the U.S. Preventive Services Task Force against routine PSA testing for healthy men age 50 and older goes too far, says a prostate cancer expert at the Siteman Cancer ...

Many men with prostate cancer can avoid early surgery

July 19, 2012
(Medical Xpress) -- New research suggests that many men with prostate cancer do not need immediate treatment, especially if they have low PSA scores or low-risk tumors that are unlikely to grow and spread.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.